Starting July 1, 2026, eligible people with Medicare Part D coverage may qualify for certain GLP-1 weight-loss medications through a new CMS program called the Medicare GLP-1 Bridge
Agreeing with our previous results (22), deletion of hepatocyte Dpp4 led to sustained reductions in plasma and hepatic DPP4 activities, with little change in circulating DPP4 protein levels (Figure 3D)
Eligibility and participation To qualify for coverage of eligible GLP-1 drugs via the Medicare GLP-1 Bridge, Medicare beneficiaries must meet certain prior authorization criteria and be enrolled in a standalone prescription drug plan (PDP) or Medicare Advantage (MA) coordinated care plan (i } Beneficiaries enrolled in private fee-for-service plans, section 1876 cost contract plans, section 1833 health care prepayment plans, PACE organizations, fallback plans, and religious fraternal benefit plans are not eligible to participate, unless also enrolled in a standalone PDP, as applicable
And when were dealing with medications that affect metabolism and hunger signals, even small measurement errors can lead to serious health consequences
